Biota Holdings Limited Announces Relenza Royalty for December 2009 Quarter

MELBOURNE, Australia--(BUSINESS WIRE)--Biota Holdings Limited (ASX:BTA) today announced that it had received written notification from GlaxoSmithKline that Relenza sales were $462 million and indicative royalties were $32.6 million, for the three months ended 31 December 2009. The figures were calculated on an Australian dollar exchange rate of 1.8182 to the UK pound, although the actual payment will be calculated on exchange rates at 30 April 2010.

Back to news